ERBB2 and neoplasm: For instance, TNBC's unique metabolic demands, driven by glycolytic dominance rather than lipid dependency, might render CD36 loss advantageous for tumor progression, whereas lipid‐rich luminal/HER2+ microenvironments could exploit CD36‐mediated FA transport to fuel metastatic growth.